Akso Health Group — Form 20-F Summary
Reporting period: Fiscal year ended March 31, 2024. This is an annual report, not a standalone 2023 fourth-quarter filing. Financial statements are prepared under U.S. GAAP and audited by OneStop Assurance PAC. The auditor issued an unqualified opinion but highlighted substantial doubt about the company’s ability to continue as a going concern.
Business context
Akso is a Cayman Islands holding company whose operations are conducted through subsidiaries. After selling its social e-commerce business in May 2023, it focused on healthcare products and medical-device sales. Fiscal 2024 revenue came entirely from medical-device sales in China; COVID-19 test-kit sales ceased. The company is also pursuing online hospital and pharmacy opportunities in China and has described plans for U.S. oncology centers, but provides no quantified current operating guidance.
Financial performance and position
| Metric | FY ended March 31, 2024 | Prior comparable period |
|---|---|---|
| Revenue | $2.42 million | $13.19 million in FY2023 |
| Gross profit / margin | $122,132 / approximately 5.1% | $1.27 million / approximately 9.6% |
| Operating expenses | $8.76 million | $15.54 million |
| Loss from continuing operations, after tax | $9.12 million | $13.08 million |
| Net loss | $9.52 million | $1.25 million |
| Operating cash flow | $1.35 million; $0.71 million from continuing operations | $(3.25) million total |
| Investing cash flow | $(54.72) million | $18.47 million |
| Financing cash flow | $131.65 million | $(27.51) million |
| Cash and cash equivalents | $85.17 million | $7.92 million |
| Total assets / liabilities | $142.02 million / $3.59 million | $20.46 million / $11.62 million |
Revenue fell 81.7%, principally because COVID-19 test-kit sales stopped. Gross profit declined sharply, leaving gross margin near 5%. General and administrative expense fell 44.7% to $8.59 million, mainly reflecting lower provisions for uncollected receivables; the company nevertheless recorded a $7.37 million provision for doubtful accounts in the cash-flow reconciliation, and year-end accounts receivable was fully reserved. Net loss widened year over year because FY2023 included $11.84 million of income from discontinued operations; FY2024 included a $0.40 million loss from discontinued operations, including a $0.40 million loss on disposal.
Cash increased mainly due to private-placement proceeds. Investing outflow included $56.25 million paid toward the acquisition of a 50% interest in Tianjin Wangyi Cloud. The company reported $138.4 million of working capital, excluding amounts due from related parties. Year-end liabilities included $2.0 million due to a related-party shareholder, interest-free and extended to August 2024; the SOS NY loan had been repaid. PRC restrictions may limit the transfer of cash held in China. The company paid no dividends after August 2018.
Material changes, outlook, risks and unusual items
- Business transition: The May 2023 sale of social e-commerce ended that business. COVID-19 test-kit revenue was nil in FY2024, leaving medical-device sales as the sole revenue source.
- Acquisition and capital allocation: The company agreed to acquire 50% of Tianjin Wangyi Cloud for $75 million, paid $56.25 million by March 31, 2024, and completed the transaction on April 15, 2024 after paying the remaining $18.75 million.
- Financing and dilution: FY2024 private placements generated $139.34 million net cash proceeds. The company reported 437.17 million ordinary shares outstanding at year-end and 290.23 million warrants outstanding, exercisable for a reported 481.65 million shares. These securities present significant potential dilution.
- Subsequent financing and governance: After year-end, the company re-designated its shares into Class A and Class B; Class B shares carry 20 votes per share. A June 2024 offering was reported as approximately $62.6 million, with shares and warrants. The filing’s description gives an apparently inconsistent closing date for that offering; verify against subsequent filings.
- Going concern: The auditor cited FY2024 net loss of approximately $9.5 million and substantial doubt about continued operations. Management said available resources should cover working capital for the next 12 months, but the financial statements include no adjustments for a possible failure to continue as a going concern.
- Concentration and execution: One supplier represented 100% of FY2024 purchases. Three customers represented approximately 36.3%, 34.8% and 28.0% of revenue. The company has no long-term customer or supplier contracts. Oncology-center expansion is an aspirational plan exposed to funding, regulatory, hiring, utilization and profitability risks; no firm timetable or financial targets are provided.
- Regulatory and structural risks: The company identifies PRC regulatory, data-security, foreign-exchange and cash-transfer risks. It says it is not currently required to obtain PRC approval for its existing overseas listing, but future offerings may require CSRC filings. VIE arrangements are described as legally uncertain and untested in court.
- Disclosure items to reconcile: The filing says the current structure contains no mainland China VIE and that the social e-commerce disposal removed VIEs from consolidation, yet other sections describe VIE agreements and present VIE financial information. It also states that Qingdao Akso’s Class III medical-device license expired on March 2, 2022 while elsewhere describing required licenses as obtained and operations as permitted. Clarify current structure and license status.
- Other: The company says management considered internal controls effective at March 31, 2024; the auditor did not attest to internal-control effectiveness. No contingent liabilities were assessed as probable at year-end. The filing also identifies employee-benefit contribution compliance and uninsured-business-loss risks.
Important facts for investors to verify
- Whether cash is accessible for planned spending, including the $75 million acquisition, and whether management’s liquidity assessment addresses the auditor’s going-concern warning.
- The acquisition’s final accounting, operating contribution and funding impact after its April 2024 completion.
- Current medical-device licenses, especially the Class III license, and the permits required for any new healthcare or oncology activities.
- The actual post-offering share count, warrant terms and potential dilution, including subsequent warrant exercises and the June 2024 financing.
- Current consolidated entities and VIE status, and how much cash is held in PRC entities versus offshore entities.
- Whether the receivable allowance and customer collections fully reflect credit risk, given the full reserve against year-end gross receivables.
- Whether supplier and customer concentration has changed and whether the company has secured alternative supply and sales arrangements.